Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase I Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Adverum Biotechnologies, Inc. announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase I clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (AMD).